Description

CJC-1295 (NO DAC) / Ipamorelin Blend — Research Protocol Overview

Typical Research Dosing Range

• 100–300 mcg per administration 
• Standard protocol:
  • Administered 1–2 times daily

Click to access Protocols-3.pdf

Timing

• Morning (fasted administration)
• Evening / pre-sleep administration
• Optional post-training dose (advanced protocols)

Cycle Length

• 8–16 weeks (active phase)
• 2–4 weeks (washout period)

Stack Options (Research Context)

• Support for growth hormone secretion
• IGF-1 LR3 (downstream anabolic signaling support)
• HGH (advanced protocols)
• L-Carnitine (fat metabolism support)

Expected Effects

• Increased endogenous growth hormone release
• Elevated IGF-1 levels
• Enhanced recovery and tissue repair
• Reduction in fat mass
• Improved sleep quality and recovery processes